KINIKSA PHARMACEUTICALS INTE (KNSA) Stock News
NASDAQ:KNSA - Nasdaq - GB00BRXB0C07 - Common Stock - Currency: USD
KNSA Latest News, Press Relases and Analysis
Kiniksa Pharmaceuticals Announces Trial Design of Planned Phase 2/3 Clinical Trial of KPL-387 in Recurrent Pericarditis
– KPL-387 Phase 2/3 trial on track to initiate in mid-2025; Phase 2 data expected in 2H 2026 –– KPL-387 Phase 1 single ascending dose data support profile...
Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences
LONDON, May 29, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will present at the...
Pony AI, Hims & Hers And Frontdoor Are Among Top 11 Mid-Cap Gainers Last Week (Apr 28-May 2): Are The Others In Your Portfolio?
Top performers last week: PONY, HIMS, ODD, MTSR, CGON, KNSA, KC, FTDR, ATI, PRDO, and IRTC. Have you invested in them?
Kiniksa Pharmaceuticals Announces GRAMMY® Award-Winning Country Star, Carly Pearce, Joins the Life DisRPted™ Campaign, Adding to Voices Advocating for Awareness of Recurrent Pericarditis
– Pearce joins NHL Hall-of-Famer, Henrik Lundqvist, to educate patients and caregivers about the importance of accurate and early diagnosis of recurrent...
Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results and Recent Portfolio Execution
– ARCALYST® (rilonacept) Q1 2025 net product revenue of $137.8 million, representing 75% year-over-year growth –– ARCALYST 2025 expected net product...
Kiniksa Pharmaceuticals to Report First Quarter 2025 Financial Results on April 29, 2025
LONDON, April 24, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call...
ADC Therapeutics SA (ADCT) Reports Q4 Loss, Misses Revenue Estimates
ADC Therapeutics (ADCT) delivered earnings and revenue surprises of 17.14% and 14.01%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Mentions: ADCT
3 No-Brainer Healthcare Stocks to Buy With $1,000 Right Now
Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Portfolio Execution
– ARCALYST® (rilonacept) Q4 2024 and full year 2024 net product revenue of $122.5 million and $417.0 million, respectively –– ARCALYST 2025 net product...
Kiniksa Pharmaceuticals Announces Development of KPL-387 in Recurrent Pericarditis and Updates Corporate Strategy
– Kiniksa plans to initiate a Phase 2/3 clinical trial of KPL-387 in recurrent pericarditis in mid-2025 – – KPL-387 Phase 1 single ascending dose data...
Kiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025
LONDON, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call...
Kiniksa Pharmaceuticals Reports Preliminary 2024 Net Product Revenue and Provides 2025 Net Product Revenue Guidance
– ARCALYST® (rilonacept) 2024 net product revenue of $416.4 million (unaudited), representing ~79% year-over-year growth –– ARCALYST 2025 net product...
Kiniksa Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference
LONDON, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that it will present at the 43rd...
Kiniksa Pharmaceuticals to Present at 7th Annual Evercore ISI HealthCONx Conference
LONDON, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a...
Kiniksa Pharmaceuticals to Present at Jefferies London Healthcare Conference
LONDON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a...
Kiniksa Pharmaceuticals Reports Third Quarter 2024 Financial Results and Recent Portfolio Execution
– ARCALYST® (rilonacept) Q3 2024 net product revenue of $112.2 million, representing 73% year-over-year growth –– ARCALYST 2024 expected net product...
Kiniksa Pharmaceuticals Partners with GRAMMY® Award-Winning Singer-Songwriter, Carly Pearce, in Expansion of Life DisRPted™ Campaign to Drive Awareness of Recurrent Pericarditis
– National campaign to elevate experiences from the recurrent pericarditis community and empower patients to seek care – LONDON, Oct. 28, 2024 (GLOBE...
Kiniksa Pharmaceuticals to Report Third Quarter 2024 Financial Results on October 29, 2024
LONDON, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call...
NHL Hall-of-Famer, Henrik Lundqvist, Teams Up with Kiniksa Pharmaceuticals to Launch Life DisRPted™ Campaign to Drive Awareness of Recurrent Pericarditis
– Life DisRPted is an educational campaign aimed at promoting early diagnosis and treatment of recurrent pericarditis, a painful and debilitating chronic autoinflammatory disease –
Kiniksa Pharmaceuticals to Present at 2024 Wells Fargo Healthcare Conference
LONDON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a...
KNSA Stock Earnings: Kiniksa Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Kiniksa Pharmaceuticals (NASDAQ:KNSA) just reported results for the second quar...